The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Albert Salehi

S Albert Salehi

Research team manager

Albert Salehi

Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion

Author

  • Elisa Vergari
  • Jakob G Knudsen
  • Reshma Ramracheya
  • Albert Salehi
  • Quan Zhang
  • Julie Adam
  • Ingrid Wernstedt Asterholm
  • Anna Benrick
  • Linford J B Briant
  • Margarita V Chibalina
  • Fiona M Gribble
  • Alexander Hamilton
  • Benoit Hastoy
  • Frank Reimann
  • Nils J G Rorsman
  • Ioannis I Spiliotis
  • Andrei Tarasov
  • Yanling Wu
  • Frances M Ashcroft
  • Patrik Rorsman

Summary, in English

Hypoglycaemia (low plasma glucose) is a serious and potentially fatal complication of insulin-treated diabetes. In healthy individuals, hypoglycaemia triggers glucagon secretion, which restores normal plasma glucose levels by stimulation of hepatic glucose production. This counterregulatory mechanism is impaired in diabetes. Here we show in mice that therapeutic concentrations of insulin inhibit glucagon secretion by an indirect (paracrine) mechanism mediated by stimulation of intra-islet somatostatin release. Insulin's capacity to inhibit glucagon secretion is lost following genetic ablation of insulin receptors in the somatostatin-secreting δ-cells, when insulin-induced somatostatin secretion is suppressed by dapagliflozin (an inhibitor of sodium-glucose co-tranporter-2; SGLT2) or when the action of secreted somatostatin is prevented by somatostatin receptor (SSTR) antagonists. Administration of these compounds in vivo antagonises insulin's hypoglycaemic effect. We extend these data to isolated human islets. We propose that SSTR or SGLT2 antagonists should be considered as adjuncts to insulin in diabetes therapy.

Department/s

  • EXODIAB: Excellence of Diabetes Research in Sweden

Publishing year

2019-01-11

Language

English

Publication/Series

Nature Communications

Volume

10

Issue

1

Document type

Journal article

Publisher

Nature Publishing Group

Topic

  • Endocrinology and Diabetes

Keywords

  • Animals
  • Benzhydryl Compounds/pharmacology
  • Blood Glucose/analysis
  • Diabetes Mellitus/drug therapy
  • Female
  • Glucagon/metabolism
  • Glucagon-Secreting Cells/drug effects
  • Glucosides/pharmacology
  • Humans
  • Hypoglycemia/pathology
  • Insulin/metabolism
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Receptor, Insulin/genetics
  • Receptors, Somatostatin/antagonists & inhibitors
  • Sodium-Glucose Transporter 2/metabolism
  • Sodium-Glucose Transporter 2 Inhibitors/pharmacology
  • Somatostatin/metabolism

Status

Published

ISBN/ISSN/Other

  • ISSN: 2041-1723